The Beauty Health Company Stock Earnings Reports

Skin Health Systems reported Q1 2026 net sales of $64.9M (down 6.7% YoY) and adjusted EBITDA of $8.5M (up 17% YoY), with adjusted gross margin at 72.2%. Device placements were softer than expected (746 systems vs. 862 prior year) due to structural headwinds: tighter credit, longer purchasing cycles, intensified competition and secondary-market pressure. Consumables were $46.4M (down 6.1%), with ~2/3 of the decline attributable to the prior-year transition of China to a distributor model; excluding China and timing effects management views consumables as largely stable. Active installed base grew to ~36,400 systems (+4% YoY) and device churn fell ~40% YoY, signaling improved retention. Management lowered full-year revenue guidance to $280M–$295M (midpoint down ~2.5%) and expects Q2 revenue $72M–$77M, but reiterated adjusted EBITDA guidance of $35M–$45M, citing margin strength and continued cost discipline. Management is taking direct commercial actions (leadership change; CEO assuming closer sales oversight), reworking booster portfolio (HydraScalp/Keravive relaunch and a clinically backed booster in Q4), pursuing strategic partnerships, and investing in a next-generation Hydrafacial targeted for 2028. Cash position was $204.4M; the company expects to be able to address an October 2026 ~$103M debt maturity based on current cash and expected cash generation. Management frames 2026 as an "execution/stabilization" year with recovery targeted for 2027+ and is prioritizing improving device conversion, utilization of the installed base, booster attachment rates, and commercial execution.